Here are three points:
1. In addition to Richard Gorelick, four other Integra LifeSciences executives reported share trades in the last month.
2. The company has a one-year high of $72.05 and a one-year low of $54.75.
3. The company’s consensus rating is “strong buy” and the average price target is $79.67 from all the analysts covering the stock.
More articles on devices:
Spineology releases Palisade Pedicular Fixation System: 4 key notes
Spinal Simplicity invests with Nueterra — 5 notes
Bone Therapeutics completes recruitment for next phase of spinal fusion study: 4 points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
